CA-SCIENTIST.COM
1.4.2021 13:57:06 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading marketplace for life science research, announced today that it has partnered with Charles River , Certis Oncology and other leading oncology CROs to launch a Disease Model Finder that helps medical researchers use genetic, cellular and patient data to find the most appropriate research models for their preclinical development projects.
“Our proprietary model selection software uses multiple machine learning algorithms to help researchers sift through large amounts of data and identify in vitro and in vivo models for their research,” stated Javier Pineda, PhD, Data Scientist at Scientist.com. “Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.”
The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models. DNA sequencing data from CRO partners is uploaded and analyzed so that researchers can easily search for models based on the presence (or absence) of a mutated gene or by the up or down regulation of gene expression. Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
“Scientist.com’s new Disease Model Finder will enable pharma and biotech researchers to find and purchase the most appropriate Charles River models for their drug development programs,” said Melissa Schroeder, E-Commerce Manager at Charles River. “Having access to advanced data that better matches a patient-derived xenograft (PDX) model with a research program will enable optimal study design, ultimately saving time and money as clients race to get critical therapies to patients.”
At launch, the Disease Model Finder includes 650 PDX models provided by Charles River, Certis, XenTech , the Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) and others—a number that is projected to grow quickly as more CROs join the program. By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.
“With so many drugs failing in human clinical trials because they don’t work, it is imperative that we use more predictive preclinical models of disease,” stated Peter Ellman, Certis Oncology CEO. “By combining gene analysis, patient data and tissue profiling data, Scientist.com’s Disease Model Finder increases the odds that researchers are selecting the right Certis models for translational drug development.”
To learn more please visit https://www.scientist.com/disease-model-finder/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons opens office in Madrid, betting on a promising pool of tech talent5.8.2026 09:00:00 CEST | Press release
Bending Spoons, the technology company behind products such as WeTransfer and Meetup, has opened an office in Madrid. The decision is underpinned by Spain’s strong talent pool, fuelled by excellent universities, and by Madrid’s international appeal and its quality of life. “We’re impressed by the talent we’ve seen in Spain. This year, we’ve received around 10,000 Spain-based applicants every month, and many of them perform among the very best candidates in our selection process. The calibre of education offered by Spanish universities is particularly high, and over the next few years we’re hoping to grow our team in Madrid into the hundreds,” says Andrea Maiorana, talent data lead. Located in the Recoletos area, the office is the company’s third European base, following the Milan headquarters and the recently opened London branch. The office is in one of the city's most coveted locations, within walking distance of Retiro Park and the Prado Museum. For new hires relocating to Madrid, B
Moove Raises $250 Million at $2.1 Billion Valuation to Scale the Global Infrastructure Layer for Autonomous Mobility5.8.2026 09:00:00 CEST | Press release
Led by Mubadala Investment Company "Mubadala", and co-led by Woven Capital (Toyota) and Ion Pacific, the Series C accelerates Moove’s global infrastructure platform for autonomous mobility as the market shifts from breakthrough technology to scaled deployment.$250 million Series C values Moove at $2.1 billion, cementing its position as the category defining infrastructure company for the autonomous mobility economyMoove is building the core operating layer for autonomous mobility globally through integrated fleet management, robotics-first depot infrastructure, and 24/7 operationsThrough its partnership with Waymo, Moove is already a leading third-party autonomous vehicle fleet manager, with operations live or announced across Phoenix, Miami and LondonMoove’s autonomous strategy is grounded in five years of building and operating mobility infrastructure at scale, from an initial launch of 76 vehicles in Lagos to approximately 42,000 vehicles across 29 cities (13 countries) and achievin
Network X Awards 2026 Finalists Announced, Spotlighting Telecom Innovation and Industry Excellence5.8.2026 08:00:00 CEST | Press release
Defining innovators recognised across AI, fibre, mobile networks, Wi-Fi and data centre infrastructure in Vienna Network X, the global event series bringing together the international fixed-line, transport and mobile telecom communities, today announced finalists for the fifth annual 2026 Network X Awards, recognising the companies, technologies and projects driving innovation across the global telecommunications industry. Celebrating excellence across 21 solution provider and operator categories, winners will be announced on 14 October during an awards ceremony at the Museum of Applied Arts (MAK) in Vienna. “The Network X Awards recognise the technologies, solutions and industry leaders actively shaping the next generation of global connectivity,” said Chris Lycett, Event Director, Network X. “With more companies entering than ever before, this year was the most competitive process to date. The finalists reflect an industry undergoing rapid transformation, from AI-driven network opera
European AI Startups Grab Record 55% of VC Capital as H1 Funding Reaches $23B5.8.2026 00:01:00 CEST | Press release
New HumanX/Crunchbase data shows a 130% YoY surge, though 73% of capital concentrated in just 38 breakout deals European AI startups raised a record-breaking $23 billion in the first half of 2026, a 130% year-over-year surge that captured 55% of all venture capital in the region, according to the 2026 European AI Economy Report released today by HumanX and Crunchbase. Up from $10 billion in H1 2025, the historic funding total signals that Europe is rapidly asserting itself as a primary engine of global AI innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804090835/en/ "If the AI story was supposed to be a two-horse race, Europe didn't get the memo," said Stefan Weitz, Co-Founder and CEO of HumanX. "$23 billion is flowing straight into the industries Europe already leads: robotics, healthcare, advanced manufacturing, defense. This is a continent betting on its own strengths." Capital concentrates in a small cohort
IFF Reports Second Quarter 2026 Results; Announces Use of Proceeds Plan for Food Ingredients Divestiture4.8.2026 22:15:00 CEST | Press release
Delivered Strong Sales, Profit and Cash Flow Performance in Second Quarter 2026Provides Full Year 2026 Financial Guidance on a Continuing Operations BasisAnnounces Enhanced $2.5B Share Repurchase Authorization; Including $500M Accelerated Share Repurchase in the second half of 2026 IFF (NYSE: IFF) reported financial results for the second quarter ended June 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a strong first half of 2026 on a continuing operations basis,” said Erik Fyrwald, CEO of IFF. “Performance was driven by volume growth, disciplined margin execution and robust free cash flow generation. These results reflect the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom